Comerica Bank Sells 4,111 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Comerica Bank trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 9.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,487 shares of the medical research company’s stock after selling 4,111 shares during the period. Comerica Bank’s holdings in IQVIA were worth $7,367,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Tidal Investments LLC boosted its stake in shares of IQVIA by 9.3% during the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company’s stock worth $1,417,000 after acquiring an additional 509 shares in the last quarter. Franklin Resources Inc. grew its holdings in IQVIA by 1.2% during the third quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company’s stock valued at $117,031,000 after purchasing an additional 6,011 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of IQVIA by 0.8% in the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company’s stock valued at $49,532,000 after purchasing an additional 1,750 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the last quarter. Finally, Versant Capital Management Inc boosted its holdings in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after buying an additional 93 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $153.42 on Friday. The firm has a market cap of $27.05 billion, a price-to-earnings ratio of 20.46, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The company has a 50 day moving average of $167.52 and a 200-day moving average of $191.06. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on IQV. Robert W. Baird decreased their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Barclays reiterated an “equal weight” rating and set a $170.00 price target (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Finally, BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $237.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.